Japanese drugmaker
The
Rohto plans to examine the efficacy and safety of the treatment after administering stem cells intravenously. It is scheduled to unveil the details of the test at a press conference on
The company said it will soon apply for the commencement of the clinical trial to the
The drugmaker said the safety of mesenchymal stem cells has been confirmed in clinical tests in the past to treat liver cirrhosis and heart failure.
==Kyodo
© Kyodo News International, Inc., source